Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice

Abstract

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.Financial support was received from Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (ISCIII-RETIC RD06/006) and by grants from Instituto de Salud Carlos III (grant number: MPY 1039/14 to V.B.], FIPSE (grant number: 36-0910-10) and RIS (grant number: RD12/0017/0035 y RD12/0017/0037). C.P. is supported by the Portuguese Fundação para a Ciência e Tecnologia (FCT) (grant number SFRH/BPD/77448/2011). V.B. is supported by the Miguel Servet programme from Fondo de Investigación Sanitaria (ISCIII) (grant number CP13/00098).info:eu-repo/semantics/publishedVersio